News

This license agreement is related to two targets currently under development by Novartis. The agreement includes Celyad’s intellectual property rights under United States Patent No. 9,181,527 related to

Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion

The decision follows recent interactions with the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), during which the Company learned that the committee was

It failed to demonstrate a statistically significant increase in the median period of overall survival of patients treated with Zoptrex as compared to patients treated with doxorubicin. Zoptarelin doxorubicin is

As a result, the agreement between Bristol-Myers Squibb and F-star Alpha has been terminated. Bristol-Myers Squibb’s decision is based on a prioritisation of opportunities across its oncology portfolio.

This indication is approved under Accelerated Approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description

Rydapt is indicated for use in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy to treat adult patients with newly diagnosed AML who are FLT3 mutation-positive, as

A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute’s established operating model

Enacted as part of the 2012 FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designation is intended to expedite the development and review of a potential new medicine